论文部分内容阅读
世界卫生组织(World Health Organization,WHO)免疫策略咨询委员会(Strategic Advisory Group of Experts,SAGE)2013年11月5~7日在瑞士日内瓦召开会议。本文总结了会议相关讨论、结论和建议。1 WHO免疫、疫苗和生物制品部门报告报告的重点是推动预防接种服务实现全球疫苗行动计划(Global Vaccine Action Plan,GVAP)的目标:至2015年3剂百日咳-白喉-破伤风联合疫苗(Three Doses of Diphteria,Tetanus and Pertussis Combined Vaccine,DTP3)在全球各国的接种率达到90%。这一目标需要额外每年接种DTP的婴儿达930万人。报告还提出近期取得的成功,如A群脑膜炎球菌疫苗项目及其对疾病负担和带菌率的影响,及利用温度控制链运输疫苗等。报告还更新了工作进展:疟疾S候选疫苗的Ⅲ期临床试验在部分现场的
The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) met from November 5-7, 2013 in Geneva, Switzerland. This article summarizes the discussions, conclusions and recommendations of the conference. 1 The WHO Immune, Vaccine and Biological Products Sector Report focuses on promoting vaccination services to achieve the Global Vaccine Action Plan (GVAP) goal: Three doses of the Pest-Diphtheria-Tetanus Combined Vaccine (2015) of Diphteria, Tetanus and Pertussis Combined Vaccine, DTP3) reaches 90% in all countries in the world. This goal requires an additional 9.3 million infants who receive an additional DTP every year. The report also suggests recent successes such as the meningococcal group A vaccine project and its impact on burden of disease and carriage rates, and the use of temperature controlled chain transport of vaccines. The report also updates work progress: Phase III clinical trial of malaria candidate vaccine at site